

# Roberto Iacovelli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3233480/publications.pdf>

Version: 2024-02-01

216  
papers

5,005  
citations

87888

38  
h-index

118850

62  
g-index

222  
all docs

222  
docs citations

222  
times ranked

7990  
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis. <i>European Journal of Cancer</i> , 2015, 51, 587-594.	2.8	425
2	Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2506-2518.	27.0	403
3	Metabolic phenotype of bladder cancer. <i>Cancer Treatment Reviews</i> , 2016, 45, 46-57.	7.7	201
4	Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. <i>Cancer</i> , 2013, 119, 3377-3384.	4.1	170
5	Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis. <i>Targeted Oncology</i> , 2016, 11, 143-148.	3.6	152
6	The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e645-e653.	1.9	115
7	Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. <i>Annals of Oncology</i> , 2015, 26, 2107-2113.	1.2	85
8	Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials. <i>Cancer Treatment Reviews</i> , 2014, 40, 271-275.	7.7	84
9	Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma. <i>Nature Communications</i> , 2020, 11, 4333.	12.8	82
10	Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2013, 109, 1755-1759.	6.4	79
11	Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors. <i>Annals of Surgical Oncology</i> , 2015, 22, 2094-2100.	1.5	72
12	Tumor Growth Rate Provides Useful Information to Evaluate Sorafenib and Everolimus Treatment in Metastatic Renal Cell Carcinoma Patients: An Integrated Analysis of the TARGET and RECORD Phase 3 Trial Data. <i>European Urology</i> , 2014, 65, 713-720.	1.9	71
13	Molecular markers in circulating tumour cells from metastatic colorectal cancer patients. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 2073-2077.	3.6	69
14	Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. <i>Acta Oncologica</i> , 2012, 51, 873-879.	1.8	66
15	Clinical and Pathological Features of Primary Neuroectodermal Tumor/Ewing Sarcoma of the Kidney. <i>Urology</i> , 2013, 82, 382-386.	1.0	65
16	Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 929-938.	2.4	65
17	Prostate cancer heterogeneity: Discovering novel molecular targets for therapy. <i>Cancer Treatment Reviews</i> , 2017, 54, 68-73.	7.7	64
18	First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 156-166.	4.4	61

#	ARTICLE	IF	CITATIONS
19	Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma. <i>BJU International</i> , 2012, 110, 1747-1753.	2.5	60
20	Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort. <i>European Journal of Cancer</i> , 2013, 49, 2134-2142.	2.8	60
21	Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 193, 41-47.	0.4	58
22	Chemotherapy or Targeted Therapy as Second-Line Treatment of Advanced Gastric Cancer. A Systematic Review and Meta-Analysis of Published Studies. <i>PLoS ONE</i> , 2014, 9, e108940.	2.5	55
23	Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2015, 68, 154-160.	1.9	53
24	DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 581-588.	2.4	52
25	Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma. <i>British Journal of Cancer</i> , 2014, 110, 1778-1784.	6.4	50
26	Circulating tumor cells and "suspicious objects" evaluated through CellSearch® in metastatic renal cell carcinoma. <i>Anticancer Research</i> , 2011, 31, 4219-21.	1.1	49
27	Clinical and pathological features of primary renal synovial sarcoma: analysis of 64 cases from 11 years of medical literature. <i>BJU International</i> , 2012, 110, 1449-1454.	2.5	48
28	FOLFOX-4 Chemotherapy for Patients With Unresectable or Relapsed Peritoneal Pseudomyxoma. <i>Oncologist</i> , 2014, 19, 845-850.	3.7	48
29	Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up-to-date review and meta-analysis of clinical trials. <i>International Journal of Cancer</i> , 2015, 136, 1-10.	5.1	47
30	Immune checkpoint inhibitors and prostate cancer: a new frontier?. <i>Oncology Reviews</i> , 2016, 10, 293.	1.8	47
31	Patients with sarcomatoid renal cell carcinoma "re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2020, 136, 195-203.	2.8	47
32	Inhibition of the VEGF/VEGFR Pathway Improves Survival in Advanced Kidney Cancer: A Systematic Review and Meta-Analysis. <i>Current Drug Targets</i> , 2015, 16, 164-170.	2.1	47
33	The prospect of precision therapy for renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2016, 49, 37-44.	7.7	46
34	Clinical outcome and prognostic factors in renal medullary carcinoma. A pooled analysis from 18 years of medical literature.. <i>Canadian Urological Association Journal</i> , 2015, 9, 172.	0.6	44
35	Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-analysis of clinical trials. <i>International Journal of Cancer</i> , 2014, 135, 763-773.	5.1	43
36	De novo metastatic castration sensitive prostate cancer: State of art and future perspectives. <i>Cancer Treatment Reviews</i> , 2018, 70, 67-74.	7.7	41

#	ARTICLE	IF	CITATIONS
37	Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. <i>BJU International</i> , 2012, 110, 692-698.	2.5	39
38	Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-Fluorouracil: a meta-analysis of published trials. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 1228-1237.	2.4	39
39	Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110196.	3.2	36
40	Adjuvant therapy in renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2017, 60, 152-157.	7.7	35
41	Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. <i>Lancet Oncology</i> , The, 2020, 21, 1513-1525.	10.7	35
42	Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases. <i>Clinical and Experimental Nephrology</i> , 2012, 16, 464-467.	1.6	33
43	Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, <i>RAS-BRAF</i> wild-type colorectal cancer receiving cetuximab or panitumumab. <i>International Journal of Cancer</i> , 2015, 137, 1467-1474.	5.1	33
44	The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2015, 51, 1970-1977.	2.8	31
45	Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 355-359.e1.	1.9	31
46	Past, Present and Future of Targeted Therapy in Solid Tumors. <i>Current Cancer Drug Targets</i> , 2010, 10, 433-461.	1.6	30
47	The origin of prostate metastases: emerging insights. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 765-773.	5.9	30
48	Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies. <i>European Journal of Cancer</i> , 2017, 83, 237-246.	2.8	30
49	Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e945-e951.	1.9	30
50	Everolimus and Temozolomide Are Not the Same Second-Line in Metastatic Renal Cell Carcinoma. A Systematic Review and Meta-Analysis of Literature Data. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 137-141.	1.9	28
51	Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story. <i>Cancers</i> , 2019, 11, 1525.	3.7	28
52	Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. <i>Targeted Oncology</i> , 2020, 15, 495-501.	3.6	28
53	Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma. <i>Oncotarget</i> , 2015, 6, 32161-32168.	1.8	28
54	Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 321-331.	5.9	27

#	ARTICLE	IF	CITATIONS
55	Positive Association between Preoperative Total Testosterone Levels and Risk of Positive Surgical Margins by Prostate Cancer: Results in 476 Consecutive Patients Treated Only by Radical Prostatectomy. <i>Urologia Internationalis</i> , 2018, 101, 38-46.	1.3	27
56	Role of MGMT as biomarker in colorectal cancer. <i>World Journal of Clinical Cases</i> , 2014, 2, 835.	0.8	27
57	Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer. <i>Targeted Oncology</i> , 2016, 11, 337-343.	3.6	23
58	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , 2020, 12, 84.	3.7	22
59	Combination or single-agent chemotherapy as adjuvant treatment of gastric cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 24-28.	4.4	21
60	Cabozantinib-related cardiotoxicity: a prospective analysis in a <i>real-world</i> cohort of metastatic renal cell carcinoma patients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1283-1289.	2.4	21
61	Clinical management and follow-up of squamous intraepithelial cervical lesions during pregnancy and postpartum. <i>Anticancer Research</i> , 2007, 27, 2743-6.	1.1	21
62	The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome. <i>Pathology and Oncology Research</i> , 2018, 24, 447-456.	1.9	20
63	Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 42-45.	1.3	20
64	Adverse events related to abiraterone and enzalutamide treatment: analysis of the EudraVigilance database and meta-analysis of registrational phase III studies. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 199-206.	3.9	20
65	Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis. <i>Cancer Treatment Reviews</i> , 2021, 100, 102295.	7.7	20
66	Treatment of collecting duct carcinoma: current status and future perspectives. <i>Anticancer Research</i> , 2014, 34, 1027-30.	1.1	20
67	New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis. <i>Cancer Treatment Reviews</i> , 2022, 106, 102377.	7.7	20
68	Wide spectrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach. <i>Oncotarget</i> , 2017, 8, 7328-7335.	1.8	19
69	Exceptional Response to Cabozantinib of Rapidly Evolving Brain Metastases of Renal Cell Carcinoma: A Case Report and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1069-e1071.	1.9	19
70	Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies. <i>British Journal of Cancer</i> , 2012, 107, 1227-1232.	6.4	18
71	Gain of ALK Gene Copy Number May Predict Lack of Benefit from Anti-EGFR Treatment in Patients with Advanced Colorectal Cancer and RAS-RAF-PI3KCA Wild-Type Status. <i>PLoS ONE</i> , 2014, 9, e92147.	2.5	18
72	Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer. <i>Targeted Oncology</i> , 2018, 13, 649-655.	3.6	18

#	ARTICLE	IF	CITATIONS
73	Treatment Outcome of metastatic lesions from renal cell carcinoma under Going Extra-cranial stereotactic body radiotherapy: The together retrospective study. <i>Cancer Treatment and Research Communications</i> , 2020, 22, 100161.	1.7	18
74	Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1631-1640.	2.4	17
75	Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2013, 113, 397-401.	2.9	17
76	Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study. <i>European Journal of Cancer</i> , 2015, 51, 473-481.	2.8	17
77	Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2018, 70, 112-117.	7.7	17
78	The development of PARP as a successful target for cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 161-175.	2.4	16
79	Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. <i>European Urology</i> , 2021, 80, 497-506.	1.9	16
80	Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer. <i>Targeted Oncology</i> , 2016, 11, 569-577.	3.6	15
81	Toward a genome-based treatment landscape for renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 141-152.	4.4	15
82	Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 477-488.	1.9	15
83	Circulating tumor cells in genitourinary tumors. <i>Therapeutic Advances in Urology</i> , 2018, 10, 65-77.	2.0	14
84	Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis. <i>Seminars in Oncology</i> , 2019, 46, 65-72.	2.2	14
85	Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e187-e194.	1.9	14
86	Clinical and pathological features of primary renal angiosarcoma.. <i>Canadian Urological Association Journal</i> , 2014, 8, 223.	0.6	13
87	Future perspectives for personalized immunotherapy in renal cell carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1049-1052.	3.1	13
88	Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 937-945.	3.1	13
89	Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results. <i>Journal of Translational Medicine</i> , 2019, 17, 296.	4.4	13
90	Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. <i>Future Oncology</i> , 2014, 10, 1741-1750.	2.4	12

#	ARTICLE	IF	CITATIONS
91	Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2017, 16, e191-e198.	2.3	12
92	Biomarkers of response to advanced prostate cancer therapy. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 195-205.	3.1	12
93	Genital and inguinal cutaneous toxicity in male and female patients treated with sunitinib. <i>International Journal of Dermatology</i> , 2012, 51, 221-222.	1.0	11
94	Management of Metastatic Renal Cell Carcinoma Progressed After Sunitinib or Another Antiangiogenic Treatment. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 611-615.	1.3	11
95	Prognostic Factors in Patients Receiving Third Line Targeted Therapy for Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 193, 1905-1910.	0.4	11
96	Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 324-331.	4.4	11
97	The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies. <i>Immunotherapy</i> , 2017, 9, 579-587.	2.0	11
98	Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1029-1054.	2.4	11
99	Tumor burden as an independent prognostic factor in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 397-397.	1.6	11
100	Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials. <i>Prostate Cancer and Prostatic Diseases</i> , 2013, 16, 323-327.	3.9	10
101	Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 541.e7-541.e13.	1.6	10
102	Cathepsin K Expression in Castration-Resistant Prostate Carcinoma: A Therapeutical Target for Patients at Risk for Bone Metastases. <i>International Journal of Biological Markers</i> , 2017, 32, 243-247.	1.8	10
103	Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 526.e13-526.e18.	1.6	10
104	PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer. <i>Journal of Immunotherapy</i> , 2019, 42, 269-273.	2.4	10
105	Verrucous carcinoma of the cervix: detection of carcinogenetic human papillomavirus types and their role during follow-up. <i>Anticancer Research</i> , 2007, 27, 4491-4.	1.1	10
106	Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210795.	3.2	10
107	Multimodality Treatment of Gynecomastia in Patients Receiving Antiandrogen Therapy for Prostate Cancer in the Era of Abiraterone Acetate and New Antiandrogen Molecules. <i>Oncology</i> , 2013, 84, 92-99.	1.9	9
108	Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor. <i>Future Oncology</i> , 2014, 10, 1361-1372.	2.4	9

#	ARTICLE	IF	CITATIONS
109	Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors. <i>Anti-Cancer Drugs</i> , 2017, 28, 206-212.	1.4	9
110	Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e150-e155.	1.9	9
111	The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A New Pharmacodynamic Marker?. <i>PLoS ONE</i> , 2015, 10, e0120427.	2.5	9
112	Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations. <i>Cancer Treatment Reviews</i> , 2022, 105, 102379.	7.7	9
113	Gemcitabine-Induced Extensive Skin Necrosis. <i>Case Reports in Medicine</i> , 2012, 2012, 1-3.	0.7	8
114	Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib.. <i>Canadian Urological Association Journal</i> , 2014, 8, 121.	0.6	8
115	Renal cell carcinoma in one year: Going inside the news of 2017 " A report of the main advances in RCC cancer research. <i>Cancer Treatment Reviews</i> , 2018, 67, 29-33.	7.7	8
116	PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2019, 11, 921-930.	2.0	8
117	Retrospective observational study of sunitinib administered on schedule 2/1 in patients with metastatic renal cell carcinoma (mRCC): The rainbow study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 471-471.	1.6	8
118	Abiraterone acetate in castration-resistant prostate cancer. <i>Anti-Cancer Drugs</i> , 2012, 23, 247-254.	1.4	7
119	First line treatment of metastatic renal cell carcinoma. <i>Cancer Biology and Therapy</i> , 2014, 15, 19-21.	3.4	7
120	Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 139, 83-86.	4.4	7
121	Effects of Antiangiogenetic Drugs on Microcirculation and Macrocirculation in Patients with Advanced-Stage Renal Cancer. <i>Cancers</i> , 2019, 11, 30.	3.7	7
122	The prognostic value of pain in castration-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 654-660.	3.9	7
123	MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma. <i>Journal of Clinical Pathology</i> , 2022, 75, 39-44.	2.0	7
124	The Anticancer Efficacy of Immune Checkpoint Inhibitors According to Patients's Age: A Systematic Review and Meta-Analysis. <i>Journal of Immunotherapy</i> , 2020, 43, 95-103.	2.4	7
125	Methylation study of the Paris system for reporting urinary (TPS) categories. <i>Journal of Clinical Pathology</i> , 2021, 74, 102-105.	2.0	7
126	Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?. <i>European Urology Oncology</i> , 2021, 4, 274-281.	5.4	7



#	ARTICLE	IF	CITATIONS
127	Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?. <i>Current Drug Metabolism</i> , 2017, 18, 692-699.	1.2	7
128	Prevalence of acetowhite areas in male partners of women affected by HPV and squamous intra-epithelial lesions (SIL) and their prognostic significance. <i>Anticancer Research</i> , 2006, 26, 3171-4.	1.1	7
129	Dynamic contrast-enhanced magnetic resonance imaging in the early evaluation of anti-angiogenic therapy in metastatic renal cell carcinoma. <i>Anticancer Research</i> , 2013, 33, 5663-6.	1.1	7
130	Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active?. <i>Anticancer Research</i> , 2022, 42, 1487-1493.	1.1	7
131	Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant. <i>Cancer Biology and Therapy</i> , 2012, 13, 1001-1008.	3.4	6
132	Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2015, 9, 263.	0.6	6
133	Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer. <i>Future Oncology</i> , 2016, 12, 2001-2008.	2.4	6
134	Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer. <i>Future Oncology</i> , 2018, 14, 2559-2564.	2.4	6
135	Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 798.e17-798.e24.	1.6	6
136	Second-line treatment in renal cell carcinoma: clinical experience and decision making. <i>Therapeutic Advances in Urology</i> , 2021, 13, 175628722110228.	2.0	6
137	Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. <i>Targeted Oncology</i> , 2021, 16, 625-632.	3.6	6
138	A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 148-148.	1.6	6
139	Follow-up of high-grade squamous intra-epithelial lesions (H-SILs) in human immunodeficiency virus (HIV)-positive and human papillomavirus (HPV)-positive women. analysis of risk factors. <i>Anticancer Research</i> , 2006, 26, 3167-70.	1.1	6
140	Targeted treatments in advanced renal cell carcinoma: focus on axitinib. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 107.	0.7	5
141	Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2015, 7, 286-294.	2.0	5
142	The effect of a treatment delay on outcome in metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 529.e1-529.e7.	1.6	5
143	Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter Italian study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5030-5030.	1.6	5
144	Time from Nephrectomy as a Prognostic Factor in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapies: Overall Results from a Large Cohort of Patients. <i>Oncology</i> , 2015, 88, 133-138.	1.9	4

#	ARTICLE	IF	CITATIONS
145	Renal Toxicity in Patients Treated with Anti-Pd-1 Targeted Agents for Solid Tumors. <i>Journal of Onco-Nephrology</i> , 2017, 1, 132-142.	0.6	4
146	De Novo, Progressed, and Neglected Metastatic Castration-Sensitive Prostate Cancer: Is One Therapy Fit for All?. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 482-484.	1.9	4
147	Prevalence of Prostate Cancer at Different Clinical Stages in Italy: Estimated Burden of Disease Based on a Modelling Study. <i>Biology</i> , 2021, 10, 210.	2.8	4
148	Fecal microbiota transplantation for TKI-induced diarrhea in patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 615-615.	1.6	4
149	Relationship and Predictive Role of the Dual Expression of FGFR and IL-8 in Metastatic Renal Cell Carcinoma Treated with Targeted Agents. <i>Anticancer Research</i> , 2018, 38, 3105-3110.	1.1	4
150	The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer. <i>Anticancer Research</i> , 2022, 42, 165-172.	1.1	4
151	Emerging tyrosine kinase inhibitors for the treatment of renal cancer. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 379-392.	2.4	3
152	Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience. <i>Anticancer Research</i> , 2018, 38, 4913-4918.	1.1	3
153	CARD: Randomized, open-label study of cabazitaxel (CBZ) vs abiraterone (ABI) or enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC). <i>Annals of Oncology</i> , 2019, 30, v882-v883.	1.2	3
154	Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 917-927.	1.5	3
155	NIVES study: A phase II trial of nivolumab (NIVO) plus stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4602-TPS4602.	1.6	3
156	Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone or enzalutamide in the CARD study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 16-16.	1.6	3
157	Dermatomyositis as first clinical appearance for a thymic epidermoid cell carcinoma. <i>Acta Biomedica</i> , 2010, 81, 68-71.	0.3	3
158	Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 727.	2.5	3
159	Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 498.e1-498.e9.	1.9	3
160	Neo-adjuvant and adjuvant chemotherapy in bladder cancer. <i>Annals of Oncology</i> , 2007, 18, vi162-vi163.	1.2	2
161	Is It Possible to Optimize the use of Targeted Therapies in the Treatment of Renal Cell Carcinoma?. <i>Tumori</i> , 2010, 96, 794-795.	1.1	2
162	Post-docetaxel therapy in castration resistant prostate cancer “the forest is growing in the desert. <i>Therapeutic Advances in Urology</i> , 2012, 4, 107-111.	2.0	2

#	ARTICLE	IF	CITATIONS
163	Study design and clinical evidence in mRCC. <i>Cancer Biology and Therapy</i> , 2014, 15, 486-488.	3.4	2
164	Bevacizumab treatment in the elderly patient with&nbsp;metastatic colorectal cancer. <i>Clinical Interventions in Aging</i> , 2015, 10, 127.	2.9	2
165	Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib. <i>Therapeutic Advances in Urology</i> , 2015, 7, 59-68.	2.0	2
166	Sunitinib 2 weeks on, 1 off: strengths and weaknesses. <i>Annals of Oncology</i> , 2015, 26, 1511-1512.	1.2	2
167	Drug-drug interactions between abiraterone (ABI) or enzalutamide (ENZ) and concomitant medications in patients with metastatic castration resistant prostate cancer (mCRPC). <i>Annals of Oncology</i> , 2016, 27, iv34.	1.2	2
168	Correlation between immuno-related adverse events (IRAEs) occurrence and clinical outcome in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: IRAENE trial, an Italian multi-institutional retrospective study. <i>Annals of Oncology</i> , 2018, 29, viii316.	1.2	2
169	The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma. <i>Anti-Cancer Drugs</i> , 2018, 29, 705-709.	1.4	2
170	Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC). <i>Annals of Oncology</i> , 2019, 30, v372-v373.	1.2	2
171	2021 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1203-1206.	2.4	2
172	Changes in tumor burden and IMDC class after active surveillance (AS) for metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 435-435.	1.6	2
173	Efficacy and safety in older patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone (ABI) or enzalutamide (ENZ) in the CARD study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5559-5559.	1.6	2
174	First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series. <i>World Journal of Clinical Oncology</i> , 2021, 12, 1037-1046.	2.3	2
175	Renal Cell Carcinoma: Incidence and Cost Estimation in the Era of Targeted Therapy. <i>Tumori</i> , 2010, 96, 361-361.	1.1	1
176	Neoadjuvant targeted therapy in renal cell carcinoma. <i>Nature Reviews Urology</i> , 2010, 7, 1-1.	3.8	1
177	FOLFIRI with cetuximab or bevacizumab: FIRE-3. <i>Lancet Oncology</i> , The, 2014, 15, e581.	10.7	1
178	Safety and efficacy of Cabozantinib for metastatic renal cell carcinoma (mRCC): real world data from an Italian Expanded Access Program (EAP). <i>Annals of Oncology</i> , 2017, 28, v319-v320.	1.2	1
179	ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance. <i>Pathology Research and Practice</i> , 2018, 214, 1675-1680.	2.3	1
180	Positive Association between Preoperative Total Testosterone and Lymph Node Invasion in Intermediate Risk Prostate Cancer. <i>Current Urology</i> , 2019, 12, 216-222.	0.6	1

#	ARTICLE	IF	CITATIONS
181	Cabozantinib-related pneumothorax in rapidly responding patients with renal cell carcinoma. <i>Lancet Oncology</i> , The, 2019, 20, e124.	10.7	1
182	Monitoring Patients with Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer: A Multidisciplinary Consensus Document. <i>Cancers</i> , 2019, 11, 1908.	3.7	1
183	629P Neutrophil-lymphocyte ratio (NLR) as a prognostic and predictive biomarker in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (CBZ) vs abiraterone or enzalutamide in the CARD study. <i>Annals of Oncology</i> , 2020, 31, S519-S520.	1.2	1
184	Inside prostate cancer news from the 2021 ASCO Genitourinary Cancers Symposium. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1-4.	2.4	1
185	Progression-free survival (PFS) and overall survival (OS) in patients receiving three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 431-431.	1.6	1
186	CARD: Overall survival (OS) analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel versus abiraterone or enzalutamide.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5569-5569.	1.6	1
187	Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS762-TPS762.	1.6	1
188	Renal cell carcinoma: incidence and cost estimation in the era of targeted therapy. <i>Tumori</i> , 2010, 96, 361.	1.1	1
189	Is it possible to optimize the use of targeted therapies in the treatment of renal cell carcinoma?. <i>Tumori</i> , 2010, 96, 794-5.	1.1	1
190	Hepatocellular carcinoma in Central, Eastern, and Southern Europe. What Future after the SHARP Trial?. <i>Open Medicine (Poland)</i> , 2009, 4, 138-139.	1.3	0
191	The End of Chemotherapy in Renal Cell Carcinoma: For Much But Not for All. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 522-523.	1.3	0
192	Umbilical Node as First Clinical Appearance in a Patient with a High Tumor Burden. <i>American Surgeon</i> , 2011, 77, 248-249.	0.8	0
193	Reply to "mTOR inhibitor-related pulmonary toxicity; incidence even higher". <i>Acta Oncologica</i> , 2013, 52, 1235-1235.	1.8	0
194	Salvage therapy for recurrence of bladder cancer: do we need a uniform approach?. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 397-399.	3.1	0
195	Modified BEP chemotherapy in patients with testicular germ-cell tumors treated at a Comprehensive Cancer Center. <i>Annals of Oncology</i> , 2016, 27, iv29.	1.2	0
196	Re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. <i>Eur Urol</i> 2017;71:970-8. <i>European Urology</i> , 2017, 71, e175-e176.	1.9	0
197	CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure. <i>Annals of Oncology</i> , 2017, 28, vi17.	1.2	0
198	Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study). <i>Annals of Oncology</i> , 2019, 30, v333.	1.2	0

#	ARTICLE	IF	CITATIONS
199	Use of clinical selection for intensification of therapy in metastatic castrate-resistant prostate cancer. <i>Annals of Oncology</i> , 2021, 32, 1192-1193.	1.2	0
200	Prognostic role of body composition parameters in renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4621-4621.	1.6	0
201	Overall survival (OS) in metastatic renal cell carcinoma (mRCC) sequentially treated with different targeted therapies (TTs): Results from a large cohort of patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4629-4629.	1.6	0
202	Clinical outcome (CO) and predictive factors (PRE) evaluation of young (&#x2264; 60 years) castration-resistant prostate cancer (CRPC) patients, treated with docetaxel (DOC): Preliminary results of an Italian multicenter retrospective study (CYCLOP study).. <i>Journal of Clinical Oncology</i> , 2013, 31, e16031-e16031.	1.6	0
203	Rationale and Protocol of SOAP: A Phase II Study to Evaluate the Efficacy of Sorafenib as Second-Line Treatment after Pazopanib in Patients with Advanced Renal Cell Carcinoma. <i>Tumori</i> , 2014, 100, e282-e285.	1.1	0
204	Prognostic value of flare-up phenomenon after discontinuation of sunitinib (SU) or pazopanib (PA) in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 448-448.	1.6	0
205	Patients with metastatic castration-resistant prostate cancer (mCRPC) are primary resistant (PR) to the new agent (NA)-based second line: Clinical outcomes and prognostic factors of subsequent treatment with another NA.. <i>Journal of Clinical Oncology</i> , 2017, 35, e585-e585.	1.6	0
206	Patients with metastatic castration-resistant prostate cancer (mCRPC) who are long-term responders (LTR) to the new agent (NA)-based second line: Clinical outcomes and prognostic factors of subsequent treatment with another NA.. <i>Journal of Clinical Oncology</i> , 2017, 35, 254-254.	1.6	0
207	Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in pts with metastatic castration-resistant prostate cancer (mCRPC) receiving a new agent (NA)- based third-line treatment: Final results from a multicenter Italian study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 230-230.	1.6	0
208	Localized prostate cancer genotyping: another step towards personalized therapy. <i>Translational Cancer Research</i> , 2017, 6, S246-S248.	1.0	0
209	Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) pts receiving a new agent (NA)- based third line treatment: Final results from a multicenter Italian study.. <i>Journal of Clinical Oncology</i> , 2017, 35, e16521-e16521.	1.6	0
210	The impact of kidney function on the efficacy and safety of pazopanib in metastatic renal cell carcinoma (mRCC) patients: CORE-URO-01 study.. <i>Journal of Clinical Oncology</i> , 2017, 35, e16063-e16063.	1.6	0
211	A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5050-5050.	1.6	0
212	Avelumab as single agent for patients with metastatic or locally advanced urothelial cancer PD-L1+ unfit for cisplatin: The ARIES study.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS596-TPS596.	1.6	0
213	Enzalutamide (E) re-challenge as second-line in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with first-line enzalutamide + docetaxel (D): Preliminary results of a post-progression analysis of CHEIRON trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 123-123.	1.6	0
214	PD16-08&#x2013;EFFECT OF CABAZITAXEL VS ABIRATERONE OR ENZALUTAMIDE ON PATIENT-REPORTED OUTCOMES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: A PRE-PLANNED EQ-5D-5L ANALYSIS OF THE CARD STUDY. <i>Journal of Urology</i> , 2020, 203, .	0.4	0
215	Umbilical node as first clinical appearance in a patient with a high tumor burden. <i>American Surgeon</i> , 2011, 77, E248-9.	0.8	0
216	Rationale and protocol of SOAP: a phase II study to evaluate the efficacy of sorafenib as second-line treatment after pazopanib in patients with advanced renal cell carcinoma. <i>Tumori</i> , 2014, 100, e282-5.	1.1	0